Tag results:
lymphocytes
Immune Regulation News
Dominant Negative TGF-β Receptor Type II in T Lymphocytes Promotes Anti-tumor Immunity by Modulating T Cell Subsets and Enhancing CTL Responses
[Biomedicine & Pharmacotherapy] Investigators demonstrated that dominant negative TGF-β receptor type II specifically targeting T cells decreased tumor load in tumor-bearing mice.
Endothelial Cell News
IL-6-Induced FOXO1 Activity Determines the Dynamics of Metabolism in CD8 T Cells Cross-Primed by Liver Sinusoidal Endothelial Cells
[Cell Reports] Scientists reported that high-level mitochondrial respiration and constitutive low-level glycolysis supported liver sinusoidal endothelial cells scavenger and sentinel functions
Cell Therapy News
Harnessing the Chemokine System to Home CAR-T Cells into Solid Tumors
[Cell Reports Medicine] By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis.
Cell Therapy News
CAR-Based Therapies: Opportunities for Immuno-Medicine beyond Cancer
[Nature Metabolism] Scientists discuss recent studies and emerging research aimed to extend CAR-based therapies beyond oncology in areas such as cardiometabolic disorders, autoimmunity, fibrosis and senescence.
Cell Therapy News
CD3 Engagement as a New Strategy for Allogeneic “Off-the-Shelf” T Cell Therapy
[Molecular Therapy-Oncolytics] Bi-specific T cell engager (BiTE-T) cells down-regulated CD3ε/TCRαβ on bystander T cells by releasing BiTEs.
Cell Therapy News
Tacrolimus-Resistant SARS-CoV-2-Specific T Cell Products to Prevent and Treat Severe COVID-19 in Immunosuppressed Patients
[Molecular Therapy-Methods & Clinical Development] Scientists proposed adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, Tacrolimus, for optimized performance in the immunosuppressed patient.